Recordati : Recordati renforce une nouvelle fois sa franchise maladies rares
>Acquisition d’Enjaymo dans la maladie des agglutinines froides - Recordati a annoncé vendredi dernier une nouvelle acquisition pour 825 M€ (+ jusqu’à 250 M€ de milestones commerciaux) d’Enjaymo (sutimlimab), un anticorps monoclonal développé par Sanofi dans le traitement de la maladie des agglutinines froides, une forme d’anémie rare. Le traitement, seul produit approuvé spécifiquement dans cette indication, a généré environ 100 M€ sur les 12 derniers mois (aux Etats...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.